Exonhit receives financial support from OSEO
At the beginning of the project during the first semester of 2012, an amount of €1,126,000 was paid to Exonhit. The consortium aims at developing new therapies for
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
According to the agreement, the companies will investigate the next generation of the Biological Nano Particles, Chatham’s recombinant adeno-associated virus-based gene therapy technology, through US-based hemophilia B clinical